Medavera's174; today announced the successful conclusion of the 2008 TTM's174; Congress, a four-day international medical education program addressing the neurological benefits of patient temperature modulation therapy post sudden cardiac arrest, as well as post traumatic brain, head, and spine injury, stroke and subarachnoid hemorrhage, and neonatal asphyxia, among other life-threatening states. With the 2008 program complete and vital work continuing, Medavera today also announced that the 2009 TTM Congress is now set to take place in Miami, Florida, November 4-7, 2009.
Therapeutic temperature management (TTM) treatments such as therapeutic hypothermia are increasingly of interest in critical-care cases because of the associated improved neurological
outcomes. Over 150 key medical community players participated in the just-concluded 2008 event, which took place in Barcelona, Spain, from October 1st-4th. In attendance were
cardiologists, neurologists, emergency medicine physicians, and other critical-care specialists as well as nurse practitioners and nurses from over 20 countries, including the Australia,
Austria, Belgium, Canada, Chile, China, Czech Republic, Denmark, Finland, Germany, Italy, Netherlands, Norway, Spain, Saudi Arabia, Sweden, Thailand, Ukraine, the United Kingdom, and the
United States.
The University of Massachusetts Medical School (UMMS) and Medavera facilitated continuing medical education credit to physicians and nurses in attendance. Also attending in support of
global TTM learning were exhibitors and unrestricted educational grant sponsors, including: Gold Sponsor and event co-founder Cincinnati Sub-Zero Products, Inc. (CSZ); Silver Sponsors
(alphabetically) Covidien and Gaymar Industries; and Bronze Sponsors (alphabetically) Alsius, Arizant Healthcare, INNERCOOL therapies, and Medivance's174;.
Dr. Kees Polderman, Chairman of the 2008 TTM Congress, said We are extremely pleased with the turnout for and participation in this year'ss program. The 50% gain in attendance numbers
over last year are a clear marker of the growing acceptance of patient temperature modulation therapies. We very much appreciate our faculty members's efforts and attendee dedication in
raising the bar on therapy standards, and for helping to encourage adoption of these promising therapies worldwide. We look forward to seeing all of this year'ss participants, and more,
in Miami.
Dr. Richard V. Aghababian, Associated Dean of Continuing Medical Education at UMMS, commented, The science behind this treatment modality seems sound and promising in terms of improving
patient outcome. The congress is an important opportunity for those conducting research in TTM, and those using TTM to care for patients, to confer with each other, with the goal of
improving patient outcomes.
Steven J. Berke, President and CEO of CSZ, event co-founder and lead sponsor, remarked, We are gratified at how much visibility therapeutic hypothermia treatments have gained over the
last year. With positive outcomes and best practices documented, we hope to see a therapeutic hypothermia protocols at every hospital on the globe someday.
About the TTM Congress
The TTM Congress is an annual international gathering of experts addressing current trends in therapeutic hypothermia and other patient temperature management applications. Leading
clinical researchers, physicians, critical-care nurses, and other emergency medicine professionals convene to exchange information and experience in an effort to advance successful
protocols in these life-saving treatments. Additional information about the congress is available at www.ttmcongress.net.
About Medavera
Medavera, Inc. is a medical education company headquartered in Springfield, MO. The company mission is to improve patient health by identifying educational need and transferring medical
knowledge with superior communication strategies and tools. For more information, please visit www.medavera.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed herein are forward-looking, reflect numerous assumptions, and involve risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated expectations. We undertake no obligation to release publicly any changes in events or circumstances arising after the
date hereof.